The Federal Antimonopoly Service (FAS) has announced the price for a generic version of the hepatitis C drug Daklavizar (INN daclatasvir) produced by the Russian company Pharmstandart. This information was shared on the FAS Telegram channel.
The agreed price for Daclatasvir-Alvils from “Alvils” is 29% lower than for the reference drug, and 21–52% lower than the prices for the generic version produced in Belarus. “The price for 28 tablets of 30 mg Daklatasvir-Alvils has been set at 17,000 rubles, while the cost of the same package of the reference drug is 24,000 rubles,” the service said.
According to the FAS, the agreed price for a generic drug “will increase the availability and expand the choice of such drugs for he population after the expiration of the patent for the original.”